GeoVax Labs, Inc. (GOVX)

From the record

GeoVax Labs, Inc.'s filings since 2017 show 12 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 10 times, the latest 2026-08-28); an auditor change (8-K item 4.01, the latest 2019-10-07); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2026-03-31) (its current reports).

From the record

GeoVax Labs, Inc.'s 10 filed years say what it did: revenue went from $829 thousand in fiscal 2016 to $2 million in fiscal 2025, up 13% a year; it rose in 3 of 8 years; the deepest fall was 100% from fiscal 2020 to fiscal 2023; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, GeoVax Labs, Inc. lost about 561 cents for every dollar of shareholders' money. Leverage: it owed about 40 cents per dollar of assets, and net share issuance: its share count grew 361.9% over the year (the filed statements).

From the record

GeoVax Labs, Inc.'s standing among 315 graded names in its industry family: revenue of $2 million in fiscal 2025 ranks in the bottom 30% by size; a net margin of -862.3% ranks in the bottom 32%; revenue growth of 212.5% a year over the last 3 filed years ranks in the top 7% (its annual reports).

From the record

GeoVax Labs, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dodd, David A (President, CEO, as filed), filing under that title since 2018-09-05, 8.2 years (top 22% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 16.6 years (top 1%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

GeoVax Labs, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against no long-term debt tagged leaves 48.7% of its assets as net cash, top 33% of its family; cash from operations less capital spending is -863.8% of revenue (bottom 27%); research spending of 728% of revenue (top 24%) (its annual report).

From the record

GeoVax Labs, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 212.5% a year over the last three filed years against 13% over all 10, speeding up (top 2% of its family); the newest year grew -37.1% (bottom 22%); research spending grew 25.7% a year (top 17%); capital spending grew -41% a year (bottom 28%) (its annual reports). GeoVax Labs, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

GeoVax Labs, Inc.'s newest year against its own record: revenue of $2 million in fiscal 2025 came in 91% below the $28 million its prior three years' pace pointed to (bottom 6% of its family); net income of $21 million against a prior three-year average of $22 million (bottom 42%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 8%) (its annual reports).